

# Faiz Anwer

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/916345/publications.pdf>

Version: 2024-02-01

291  
papers

1,915  
citations

361413

20  
h-index

361022

35  
g-index

291  
all docs

291  
docs citations

291  
times ranked

3327  
citing authors

#	ARTICLE	IF	CITATIONS
1	The Impact of Atrial Fibrillation on hospitalization Outcomes for Patients With Chronic Lymphocytic Leukemia Using the National Inpatient Sample Database. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2022, 22, 98-104.	0.4	5
2	Vaccine responses in patients with chronic lymphocytic leukemia on treatment with Bruton Tyrosine Kinase Inhibitors: a focused review. <i>Hematology, Transfusion and Cell Therapy</i> , 2022, 44, 293-296.	0.2	1
3	Impact of COVID-19 in hematopoietic stem cell transplant recipients: A systematic review and meta-analysis. <i>Transplant Infectious Disease</i> , 2022, 24, .	1.7	28
4	Emerging Role of Antibody-Drug Conjugates and Bispecific Antibodies for the Treatment of Multiple Myeloma. <i>Antibodies</i> , 2022, 11, 22.	2.5	1
5	The Association of Pre-Transplant Adiposity with Autologous Hematopoietic Stem Cell Transplantation Outcomes in Lymphoma. <i>Transplantation and Cellular Therapy</i> , 2022, 28, S412.	1.2	0
6	Evaluation of pre-transplant risk assessments in allogeneic hematopoietic cell transplant. <i>Bone Marrow Transplantation</i> , 2022, 57, 1031-1033.	2.4	1
7	Outcomes after venetoclax with hypomethylating agents in myelodysplastic syndromes: a systematic review and meta-analysis. <i>Leukemia and Lymphoma</i> , 2022, 63, 2671-2678.	1.3	0
8	Abnormal metaphase cytogenetics predicts venous thromboembolism in myeloma: derivation and validation of the PRISM score. <i>Blood</i> , 2022, 140, 2443-2450.	1.4	12
9	Role and mechanism of autophagy-regulating factors in tumorigenesis and drug resistance. <i>Asia-Pacific Journal of Clinical Oncology</i> , 2021, 17, 193-208.	1.1	69
10	Impact of Acquired Thrombocytopenia on Cardiovascular Outcomes in Patients With Coronary Artery Disease Undergoing Percutaneous Coronary Intervention: A Systematic Review and Meta-Analysis. <i>Cardiovascular Revascularization Medicine</i> , 2021, 27, 79-87.	0.8	0
11	Cisplatin-Mediated Upregulation of APE2 Binding to MYH9 Provokes Mitochondrial Fragmentation and Acute Kidney Injury. <i>Cancer Research</i> , 2021, 81, 713-723.	0.9	24
12	Allogeneic hematopoietic stem cell transplant in rare hematologic disorders: a single center experience from Pakistan. <i>Bone Marrow Transplantation</i> , 2021, 56, 863-872.	2.4	1
13	Allogeneic hematopoietic stem cell transplantation in aplastic anemia: current indications and transplant strategies. <i>Blood Reviews</i> , 2021, 47, 100772.	5.7	26
14	Fundamentals of Light Chain Cardiac Amyloidosis: A Focused Review. <i>Cardiovascular &amp; Hematological Disorders Drug Targets</i> , 2021, 20, 274-283.	0.7	0
15	Management of Primary Plasma Cell Leukemia Remains Challenging Even in the Era of Novel Agents. <i>Clinical Medicine Insights Blood Disorders</i> , 2021, 14, 263485352199938.	0.3	5
16	Prognostic Impact of Red Cell Distribution Width on the Development of Contrast Induced Nephropathy, Major Adverse Cardiac Events, and Mortality in Coronary Artery Disease Patients Undergoing Percutaneous Coronary Intervention.. <i>Current Cardiology Reviews</i> , 2021, 17, .	1.5	2
17	Validation of the IMPEDE VTE score for prediction of venous thromboembolism in multiple myeloma: a retrospective cohort study. <i>British Journal of Haematology</i> , 2021, 193, 1213-1219.	2.5	25
18	Arterial thromboembolism in multiple myeloma in the context of modern anti-myeloma therapy. <i>Blood Cancer Journal</i> , 2021, 11, 121.	6.2	6

#	ARTICLE	IF	CITATIONS
19	Emerging Targets and Cellular Therapy for Relapsed Refractory Multiple Myeloma: A Systematic Review. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2021, 21, 741-751.	0.4	5
20	Primary Mediastinal B-Cell Lymphoma: A 2021 Update on Genetics, Diagnosis, and Novel Therapeutics. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2021, 21, e865-e875.	0.4	13
21	Management of Relapsed Hairy Cell Leukemia: A Systematic Review of Novel Agents and Targeted Therapies. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2021, 21, 659-666.	0.4	1
22	Dawn of a new era of antibody-drug conjugates and bispecific T-cell engagers for treatment of multiple myeloma: a systematic review of literature. <i>Annals of Hematology</i> , 2021, 100, 2155-2172.	1.8	4
23	Profile and Management of Toxicity of Selinexor and Belantamab Mafodotin for the Treatment of Triple Class Refractory Multiple Myeloma. <i>Journal of Blood Medicine</i> , 2021, Volume 12, 529-550.	1.7	5
24	Special Considerations for Supportive Care and Management of Complications in Elderly Patients With Multiple Myeloma. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2021, 21, 812-822.	0.4	4
25	Carfilzomib-Based 3-Drug Regimens for Newly Diagnosed Multiple Myeloma—All That Glitters Is Not Gold. <i>JAMA Oncology</i> , 2021, 7, 967.	7.1	0
26	Isolated Gastric Amyloid Light Chain Amyloidosis Causing Upper Gastrointestinal Bleeding. <i>American Journal of Gastroenterology</i> , 2021, Publish Ahead of Print, 2165.	0.4	0
27	Incidence and Management of Carfilzomib-induced Cardiovascular Toxicity; A Systematic Review and Meta-analysis. <i>Cardiovascular &amp; Hematological Disorders Drug Targets</i> , 2021, 21, 30-45.	0.7	11
28	Advances in viral oncolytics for treatment of multiple myeloma — a focused review. <i>Expert Review of Hematology</i> , 2021, 14, 1071-1083.	2.2	3
29	Progress in research: Daratumumab improves treatment outcomes of patients with AL amyloidosis. <i>Critical Reviews in Oncology/Hematology</i> , 2021, 165, 103435.	4.4	2
30	Efficacy and Toxicity Profile of Carfilzomib-Based Regimens for Treatment of Newly Diagnosed Multiple Myeloma: A Systematic Review. <i>OncoTargets and Therapy</i> , 2021, Volume 14, 4941-4960.	2.0	4
31	Outcomes of surgical versus transcatheter aortic valve replacement in nonagenarians- a systematic review and meta-analysis. <i>Journal of Community Hospital Internal Medicine Perspectives</i> , 2021, 11, 128-134.	0.8	6
32	Outcomes and factors impacting use of axicabtagene ciloleucel in patients with relapsed or refractory large B-cell lymphoma: results from an intention-to-treat analysis. <i>Leukemia and Lymphoma</i> , 2021, 62, 1344-1352.	1.3	7
33	Efficacy and safety of recombinant thrombomodulin for the prophylaxis of veno-occlusive complication in allogeneic hematopoietic stem cell transplantation: A systematic review and meta-analysis. <i>Hematology/ Oncology and Stem Cell Therapy</i> , 2021, , .	0.9	0
34	Treatment Outcomes for Follicular Lymphoma with Progression of Disease within 24 Months of Front-Line Therapy: A Systematic Review. <i>Blood</i> , 2021, 138, 4521-4521.	1.4	0
35	Safety and Efficacy of Thrombopoietin Analogs in the Treatment of Chronic Thrombocytopenic Purpura in Children: A Systematic Review. <i>Blood</i> , 2021, 138, 4215-4215.	1.4	0
36	Clinical Outcomes in Patients Admitted with Malignancy Associated Hemophagocytic Lymphohistiocytosis (HLH). <i>Blood</i> , 2021, 138, 4199-4199.	1.4	1

#	ARTICLE	IF	CITATIONS
37	Title: Efficacy and Safety of Ferric Derisomaltose for Treatment of Anemia in Chronic Kidney Disease Patients: A Systematic Review. <i>Blood</i> , 2021, 138, 4156-4156.	1.4	0
38	Universal Updated Phase 1 Data Validates the Feasibility of Allogeneic Anti-BCMA ALLO-715 Therapy for Relapsed/Refractory Multiple Myeloma. <i>Blood</i> , 2021, 138, 651-651.	1.4	30
39	Recent Updates on Blinatumomab: A Bispecific T-Cell Engaging Antibody in Relapsed and Refractory B-Cell Acute Lymphoblastic Leukemia. <i>Blood</i> , 2021, 138, 4393-4393.	1.4	0
40	Demographics and Outcomes of Multiple Myeloma Patients Undergoing Modern Modality Treatments Proceeding to ASCT: A Retrospective Study. <i>Blood</i> , 2021, 138, 4743-4743.	1.4	0
41	Updated Organ Response Results of an Open-Label Study to Evaluate the Safety and Tolerability of Cael-101 in Patients with AL Amyloidosis Receiving Anti-Plasma Cell Therapy. <i>Blood</i> , 2021, 138, 2724-2724.	1.4	3
42	Outcomes with Venetoclax in Relapsed Acute Myeloid Leukemia after Allogeneic Hematopoietic Stem Cell Transplantation: A Systemic Review and Meta-Analysis. <i>Blood</i> , 2021, 138, 4410-4410.	1.4	0
43	Efficacy and Safety of Regimens Used for the Treatment of Multicentric Castleman Disease: A Systematic Review. <i>Blood</i> , 2021, 138, 4512-4512.	1.4	0
44	Efficacy and Safety of Ferric Derisomaltose/Iron Isomaltoside in Patients with Inflammatory Bowel Disease: A Systematic Review. <i>Blood</i> , 2021, 138, 4155-4155.	1.4	1
45	Bispecific T-Cell Engager Antibodies in Multiple Myeloma- a Systematic Review of Phase 1 Clinical Trials. <i>Blood</i> , 2021, 138, 4775-4775.	1.4	0
46	Outcomes of Haploidentical Stem Cell Transplantation in Patients with Fanconi Anemia; A Systematic Review. <i>Blood</i> , 2021, 138, 4308-4308.	1.4	0
47	Management of Myeloproliferative Neoplasms during Pregnancy: A Systematic Review. <i>Blood</i> , 2021, 138, 4642-4642.	1.4	0
48	Relapse Prevention with Tyrosine Kinase Inhibitors after Allogeneic Transplantation for Philadelphia Chromosome-Positive Acute Lymphoblast Leukemia: A Systematic Review. <i>Biology of Blood and Marrow Transplantation</i> , 2020, 26, e55-e64.	2.0	54
49	Treatment of relapsed multiple myeloma: Evidence-based recommendations. <i>Blood Reviews</i> , 2020, 39, 100616.	5.7	43
50	Revisiting Role of Vaccinations in Donors, Transplant Recipients, Immunocompromised Hosts, Travelers, and Household Contacts of Stem Cell Transplant Recipients. <i>Biology of Blood and Marrow Transplantation</i> , 2020, 26, e38-e50.	2.0	7
51	Venous thromboembolism risk with contemporary lenalidomide-based regimens despite thromboprophylaxis in multiple myeloma: A systematic review and meta-analysis. <i>Cancer</i> , 2020, 126, 1640-1650.	4.1	28
52	Therapeutic Advances in the Management of Smoldering Myeloma. <i>American Journal of Therapeutics</i> , 2020, 27, e194-e203.	0.9	0
53	Advances in maintenance strategy in newly diagnosed multiple myeloma patients eligible for autologous transplantation. <i>Expert Review of Hematology</i> , 2020, 13, 1333-1347.	2.2	1
54	COVID-19 in Cancer Patients From New York City: A Comparative Single Center Retrospective Analysis. <i>Cancer Control</i> , 2020, 27, 107327482096045.	1.8	15

#	ARTICLE	IF	CITATIONS
55	Obstructive sleep apnea and peripheral vascular disease: a systematic review based on current literature. <i>Journal of Community Hospital Internal Medicine Perspectives</i> , 2020, 10, 188-193.	0.8	4
56	&lt;p&gt;A Systematic Review of Transfusion-Transmissible Infections Among Blood Donors and Associated Safety Challenges in Pakistan&lt;/p&gt;. <i>Journal of Blood Medicine</i> , 2020, Volume 11, 405-420.	1.7	11
57	Single-Agent Cyclosporine for Graft-versus-Host Disease Prophylaxis in Patients with Acquired Aplastic Anemia Receiving Fludarabine-Based Conditioning. <i>Biology of Blood and Marrow Transplantation</i> , 2020, 26, 2245-2251.	2.0	1
58	Low morbidity and mortality with COVIDâ€19 in sickle cell disease: A single center experience. <i>EJHaem</i> , 2020, 1, 608-614.	1.0	19
59	Evidence-based supportive care in multiple myeloma. <i>Journal of Community Hospital Internal Medicine Perspectives</i> , 2020, 10, 313-317.	0.8	1
60	Survival following relapse after allogeneic hematopoietic cell transplantation for acute leukemia and myelodysplastic syndromes in the contemporary era. <i>Hematology/ Oncology and Stem Cell Therapy</i> , 2020, 14, 318-326.	0.9	7
61	Risk of kidney toxicity with carfilzomib in multiple myeloma: a meta-analysis of randomized controlled trials. <i>Annals of Hematology</i> , 2020, 99, 1265-1271.	1.8	18
62	A Single-Center Experience and Literature Review of Management Strategies for Clostridium difficile Infection in Hematopoietic Stem Cell Transplant Patients. <i>Infectious Diseases in Clinical Practice</i> , 2020, 28, 10-15.	0.3	2
63	Atrial fibrillation and cancer; understanding the mysterious relationship through a systematic review. <i>Journal of Community Hospital Internal Medicine Perspectives</i> , 2020, 10, 127-132.	0.8	17
64	Characterisation and prognostic impact of immunoparesis in relapsed multiple myeloma. <i>British Journal of Haematology</i> , 2020, 189, 1074-1082.	2.5	11
65	Targeted Treatment and Survival Following Relapse after Allogeneic Hematopoietic Cell Transplantation for Acute Leukemia and Myelodysplastic Syndrome in the Contemporary Era. <i>Biology of Blood and Marrow Transplantation</i> , 2020, 26, S117-S118.	2.0	0
66	The Impact of Clinical Pharmacists in Hematopoietic Stem Cell Transplant (HSCT) Outpatient Clinic at an Academic Medical Center. <i>Biology of Blood and Marrow Transplantation</i> , 2020, 26, S93.	2.0	0
67	Toxicity Analysis of Busulfan Pharmacokinetic Guided Therapeutic Dose Monitoring for Myeloablative Conditioning Regimens with Allogeneic Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2020, 26, S388-S389.	2.0	0
68	Daratumumab-based Regimen in Treating Clonal Plasma Cell Neoplasms in Solid Organ Transplant Recipients. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2020, 20, e137-e143.	0.4	12
69	Novel Targeted Therapies for Chronic Lymphocytic Leukemia in Elderly Patients: A Systematic Review. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2020, 20, e414-e426.	0.4	6
70	Safety, Tolerability and Efficacy of Cael-101 in AL Amyloidosis Patients Treated on a Phase 2, Open-Label, Dose Selection Study to Evaluate the Safety and Tolerability of Cael-101 in Patients with AL Amyloidosis. <i>Blood</i> , 2020, 136, 21-21.	1.4	9
71	Efficacy of Selinexor Based Regimens in Relapsed Refractory Multiple Myeloma: A Systematic Review. <i>Blood</i> , 2020, 136, 13-13.	1.4	1
72	Efficacy of Venetoclax Based Regimens in Relapsed Refractory Multiple Myeloma: A Systematic Review and Meta-Analysis. <i>Blood</i> , 2020, 136, 39-40.	1.4	2

#	ARTICLE	IF	CITATIONS
73	Comparison of Conventional Cyclophosphamide <i>versus</i> Fludarabine-Based Conditioning in High-Risk Aplastic Anemia Patients Undergoing Matched-Related Donor Transplantation. <i>Clinical Hematology International</i> , 2020, 2, 82.	1.7	1
74	Prevalence of Transfusion Transmissible Infections in Beta-Thalassemia Major Patients in Pakistan: A Systemic Review. <i>Cureus</i> , 2020, 12, e10070.	0.5	16
75	The Potential Vaccine Component for COVID-19: A Comprehensive Review of Global Vaccine Development Efforts. <i>Cureus</i> , 2020, 12, e8871.	0.5	13
76	Safety and Efficacy of Ruxolitinib in Steroid-Resistant Graft Versus Host Disease: A Systematic Review and Meta-Analysis. <i>Blood</i> , 2020, 136, 23-24.	1.4	0
77	Abnormal Metaphase Cytogenetics Adds to Currently Known Risk-Factors for Venous Thromboembolism in Multiple Myeloma: Derivation of the <i>PRISM</i> score. <i>Blood</i> , 2020, 136, 29-30.	1.4	2
78	Spleen and Symptom Responses of JAK Inhibitors in Myelofibrosis; A Systematic Review of Phase 2 and 3 Trials. <i>Blood</i> , 2020, 136, 26-27.	1.4	0
79	Novel Therapies for the Treatment of Patients with Relapsed/Refractory Multiple Myeloma: A Review of Clinical Trials. <i>Blood</i> , 2020, 136, 43-44.	1.4	0
80	Efficacy and Safety of Phosphoinositide 3-Kinase (PI3K) Inhibitors in Non-Hodgkin's Lymphoma: A Systematic Review and Meta-Analysis. <i>Blood</i> , 2020, 136, 12-13.	1.4	1
81	Role of Hypomethylating Agents in Accelerated and Blast Phase of Philadelphia Negative Myeloproliferative Neoplasms: A Systematic Review. <i>Blood</i> , 2020, 136, 20-21.	1.4	0
82	A Systematic Review on Efficacy and Safety of Bortezomib Based Regimens for Treatment of Waldenstrom Macroglobulinemia. <i>Blood</i> , 2020, 136, 12-12.	1.4	0
83	Resource Utilization and Factors Prolonging Hospitalization for Patients with Relapsed and Refractory Large B-Cell Lymphoma Receiving Tisagenlecleucel Versus Axicabtagene Ciloleucel. <i>Blood</i> , 2020, 136, 38-39.	1.4	2
84	Efficacy and Safety of Blinatumomab for Relapsed or Refractory Pediatric ALL Patients: A Systematic Review. <i>Blood</i> , 2020, 136, 22-23.	1.4	1
85	Clinical Outcomes of Malignancy-Related Neutropenic Fever Admissions in the United States: A 10-Year National Study. <i>Blood</i> , 2020, 136, 43-44.	1.4	0
86	Efficacy of Ixazomib and Bortezomib with Lenalidomide Combination Regimens for Multiple Myeloma: A Systematic Review. <i>Blood</i> , 2020, 136, 40-41.	1.4	1
87	Dartumumab in Pretreated AL Amyloidosis: A Systematic Review. <i>Blood</i> , 2020, 136, 46-47.	1.4	0
88	A Systematic Review of Daratumumab Based Four Drug Regimen for Newly Diagnosed Multiple Myeloma in Phase III Clinical Trials. <i>Blood</i> , 2020, 136, 36-37.	1.4	1
89	Efficacy and Safety of Isatuximab in Relapsed Refractory Multiple Myeloma: A Systematic Review. <i>Blood</i> , 2020, 136, 8-9.	1.4	0
90	Reduced-Intensity Versus Myeloablative Conditioning for Allogeneic Hematopoietic Cell Transplantation in Patients with Myelodysplastic Syndrome: A Systematic Review and Meta-Analysis of Randomized Clinical Trials & Cohort Studies. <i>Blood</i> , 2020, 136, 25-26.	1.4	0

#	ARTICLE	IF	CITATIONS
91	Maintenance Therapy in Newly Diagnosed and Transplant Ineligible Multiple Myeloma Patients: A Meta-Analysis. Blood, 2020, 136, 15-16.	1.4	0
92	Efficacy and Safety Profile of Ixazomib Based Regimens in Relapsed/Refractory Multiple Myeloma: A Meta-Analysis of Clinical Trials. Blood, 2020, 136, 20-21.	1.4	0
93	Efficacy of Four Drug Regimens in Multiple Myeloma: A Systemic Review. Blood, 2020, 136, 21-22.	1.4	0
94	A Systematic Review of High Dose Chemotherapy with Autologous Transplantation in Secondary CNS Lymphoma. Blood, 2020, 136, 14-14.	1.4	0
95	Efficacy of Chemotherapeutic Regimens for Mantle Cell Lymphoma: A Systematic Review of Phase III Trials. Blood, 2020, 136, 6-7.	1.4	0
96	Safety and Efficacy of Purine Analogs for Treatment of Waldenstrom Macroglobulinemia. Blood, 2020, 136, 9-10.	1.4	0
97	Ixazomib Based Regimens in Patients with Newly Diagnosed Multiple Myeloma: A Systematic Review and Meta-Analysis of Clinical Trials. Blood, 2020, 136, 35-35.	1.4	0
98	Post-Transplant Lymphoproliferative Disorder after Renal Transplant in the Pediatric Population: A Systematic Review. Blood, 2020, 136, 35-36.	1.4	1
99	A Systematic Review and Meta-Analysis of Luspatercept for Anemia Treatment in Low Risk Myelodysplastic Syndrome with Ring Sideroblast Subtype in Phase II and Phase III Clinical Trials. Blood, 2020, 136, 40-41.	1.4	0
100	Systematic Review of Phase III Trials of Daratumumab Based Regimens in Relapsed Refractory Multiple Myeloma. Blood, 2020, 136, 4-5.	1.4	0
101	The Role of Checkpoint Inhibitors in Adults with Classical Hodgkin Lymphoma; A Systematic Review and Meta-Analysis of Phase II and III Clinical Trials. Blood, 2020, 136, 25-26.	1.4	0
102	Safety and Adverse Reactions of CAR T Therapy for the Treatment of Multiple Myeloma: A Systematic Review. Blood, 2020, 136, 6-7.	1.4	1
103	Post-Transplant Lymphoproliferative Disorder after Liver Transplant: A Systematic Review. Blood, 2020, 136, 34-35.	1.4	0
104	Rituximab and Cyclophosphamide Based Regimens for Treatment of Waldensterom Macroglobulemia, Lessons from Clinical Literature: A Systemic Review. Blood, 2020, 136, 10-11.	1.4	1
105	Emerging Role of Adoptive T Cell Therapy for EBV Induced Nasopharyngeal Carcinoma (NPC) - a Systematic Review. Blood, 2020, 136, 18-19.	1.4	1
106	Efficacy of Isatuximab on Surrogate Endpoints in Multiple Myeloma; A Systematic Review. Blood, 2020, 136, 34-34.	1.4	0
107	Efficacy and Safety of Selinexor for Acute Myeloid Leukemia: A Systematic Review. Blood, 2020, 136, 15-16.	1.4	2
108	Post-Transplant Lymphoproliferative Disorder after Solid Organ Transplant in the Pediatric Population: A Systematic Review. Blood, 2020, 136, 7-8.	1.4	0



#	ARTICLE	IF	CITATIONS
109	Role of Adoptive T- Cell Therapy in Post Hematopoietic Stem Cells Transplant Viral Infections: A Systemic Review. Blood, 2020, 136, 14-16.	1.4	0
110	CD-19 Specific CAR-T Cell Therapy in Relapsed/Refractory ALL in Pediatrics and Young Adults; Safety and Efficacy Outcomes: A Systematic Review and Meta-Analysis. Blood, 2020, 136, 10-11.	1.4	0
111	Efficacy and Safety of Recombinant Thrombomodulin for the Prophylaxis of Vaso-Occlusive Complications in Allogeneic Hematopoietic Stem Cell Transplantation : A Systematic Review and Meta-Analysis. Blood, 2020, 136, 26-27.	1.4	0
112	A Systematic Review of Phase III Clinical Trials of Daratumumab Addition to Standard Care Regimen for Newly Diagnosed Multiple Myeloma. Blood, 2020, 136, 7-7.	1.4	0
113	A Systemic Review on Efficacy of Ibrutinib-Based Regimens for the Treatment of Waldenstrom Macroglobulinemia. Blood, 2020, 136, 8-9.	1.4	1
114	Efficacy of Daratumumab Based Regimens Compared to Standard of Care for Transplant Ineligible Newly Diagnosed Multiple Myeloma in Phase III Clinical Trials: A Meta-Analysis. Blood, 2020, 136, 32-33.	1.4	0
115	Azacitidine Maintenance Following Allogeneic Hematopoietic Stem Cell Transplantation in Patients with Myelodysplastic Syndrome and Acute Myeloid Leukemia: A Systematic Review. Blood, 2020, 136, 29-30.	1.4	0
116	Hematopoietic Progenitor Cell Mobilization and Collection for Autologous Hematopoietic Cell Transplantation in AL Amyloidosis: A Single Center Experience. Blood, 2020, 136, 26-27.	1.4	0
117	Post-Transplant Lymphoproliferative Disorder after Heart Transplant in the Pediatric Population: A Systematic Review. Blood, 2020, 136, 37-37.	1.4	0
118	Post-Transplant Lymphoproliferative Disorder after Liver Transplant in the Pediatric Population: A Systematic Review. Blood, 2020, 136, 38-39.	1.4	0
119	Efficacy and Safety Profile of Proteasome Inhibitor Based Drug Regimens for Treatment of Newly Diagnosed AL Amyloidosis: A Systematic Review. Blood, 2020, 136, 31-32.	1.4	0
120	Safety and Efficacy of Tyrosine Kinase Inhibitors in Acute Myeloid Leukemia: A Systematic Review and Meta-Analysis of Randomized Clinical Trials. Blood, 2020, 136, 18-18.	1.4	1
121	Defining Quality Through a Collaborative Process for Multiple Myeloma Care. Blood, 2020, 136, 22-23.	1.4	0
122	Treatment Options for Newly Diagnosed Frail and Transplant-Ineligible Patients with Multiple Myeloma: A Systematic Review. Blood, 2020, 136, 18-19.	1.4	0
123	Efficacy of Daratumumab Based Regimens Compared to Standard of Care for Transplant Eligible Multiple Myeloma in Phase III Clinical Trials: A Meta-Analysis. Blood, 2020, 136, 36-36.	1.4	0
124	Safety and Efficacy of Four Drug Versus Three Drug Regimens Among Patients with Newly Diagnosed Multiple Myeloma: A Systematic Review and Meta-Analysis. Blood, 2020, 136, 3-3.	1.4	0
125	Risk of Thyroid Dysfunctions with Use of Immune Checkpoint Inhibitors: A Meta-Analysis of Randomized Controlled Trials. Blood, 2020, 136, 14-14.	1.4	0
126	The Comparison of Novel Oral Anticoagulants with Conventional Anticoagulants in the Treatment of Cancer-Associated Thrombosis: A Systemic Review. Blood, 2020, 136, 15-16.	1.4	0



#	ARTICLE	IF	CITATIONS
127	Efficacy and Safety of Regimens Used for the Treatment of POEMS Syndrome- a Systematic Review. <i>Blood</i> , 2020, 136, 7-7.	1.4	0
128	Risk of Serious Infections with Lenalidomide Based Regimens in Multiple Myeloma: A Network Meta-Analysis. <i>Blood</i> , 2020, 136, 12-12.	1.4	9
129	Comparing the Efficacy of Cyclophosphamide Versus Lenalidomide in Combination with Bortezomib for Newly Diagnosed Multiple Myeloma Treatment: A Systematic Review. <i>Blood</i> , 2020, 136, 42-42.	1.4	0
130	Outcome of Fludarabine-Based Conditioning in High-Risk Aplastic Anemia Patients Undergoing Matched Related Donor Transplantation: A Single-Center Study from Pakistan. <i>Biology of Blood and Marrow Transplantation</i> , 2019, 25, 2375-2382.	2.0	11
131	Fecal Calprotectin as a Diagnostic and Prognostic Biomarker for Gastrointestinal Graft Versus Host Disease: A Systematic Review of Literature. <i>Cureus</i> , 2019, 11, e4143.	0.5	6
132	The novel autophagy inhibitor ROC-325 augments the antileukemic activity of azacitidine. <i>Leukemia</i> , 2019, 33, 2971-2974.	7.2	32
133	Denosumab vs Zoledronic Acid for Bone-Targeted Therapy in Multiple Myeloma. <i>JAMA Oncology</i> , 2019, 5, 1095.	7.1	4
134	Investigational Monoclonal Antibodies in the Treatment of Multiple Myeloma: A Systematic Review of Agents under Clinical Development. <i>Antibodies</i> , 2019, 8, 34.	2.5	10
135	Conditional Survival in Patients with Multiple Myeloma Undergoing Upfront Autologous Stem Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2019, 25, S392.	2.0	0
136	Future of Personalized Therapy Targeting Aberrant Signaling Pathways in Multiple Myeloma. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2019, 19, 397-405.	0.4	13
137	Special considerations for the treatment of multiple myeloma according to advanced age, comorbidities, frailty and organ dysfunction. <i>Critical Reviews in Oncology/Hematology</i> , 2019, 137, 18-26.	4.4	12
138	Pomalidomide-Based Regimens for Treatment of Relapsed and Relapsed/Refractory Multiple Myeloma: Systematic Review and Meta-analysis of Phase 2 and 3 Clinical Trials. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2019, 19, 447-461.	0.4	11
139	A Phase I Study of Haploidentical Bone Marrow Transplantation with Post-Transplant Cyclophosphamide and/or Bendamustine. <i>Biology of Blood and Marrow Transplantation</i> , 2019, 25, S224.	2.0	1
140	Concomitant use of blinatumomab and donor lymphocyte infusion for mixed-phenotype acute leukemia: a case report with literature review. <i>Immunotherapy</i> , 2019, 11, 373-378.	2.0	22
141	Rational cotargeting of HDAC6 and BET proteins yields synergistic antimyeloma activity. <i>Blood Advances</i> , 2019, 3, 1318-1329.	5.2	20
142	Significant Risk of Graft-versus-Host Disease with Exposure to Checkpoint Inhibitors before and after Allogeneic Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2019, 25, 94-99.	2.0	140
143	Prevalence of Major Depression Among Cancer Patients: Single Center Tertiary Care Hospital Experience from Lahore, Pakistan. <i>Blood</i> , 2019, 134, 5784-5784.	1.4	1
144	Targeted Treatment and Survival Following Relapse after Allogeneic Hematopoietic Cell Transplantation for Acute Leukemia and MDS in the Contemporary Era. <i>Blood</i> , 2019, 134, 4567-4567.	1.4	3

#	ARTICLE	IF	CITATIONS
145	Outcomes and Factors Impacting Use of Axicabtagene Ciloleucel in Refractory and Relapsed Large B-Cell Lymphoma: An Intent-to-Treat Analysis. <i>Blood</i> , 2019, 134, 4452-4452.	1.4	3
146	Infections Associated with CAR T Therapy for Treatment of Hematological Malignancies. <i>Blood</i> , 2019, 134, 4442-4442.	1.4	4
147	Bispecific T-Cell Engager (BiTE) Antibody Based Immunotherapy for Treatment of Relapsed Refractory Multiple Myeloma (RRMM): A Systematic Review of Preclinical and Clinical Trials. <i>Blood</i> , 2019, 134, 5567-5567.	1.4	9
148	External Validation of the Impede VTE Risk Score in Newly Diagnosed Multiple Myeloma (MM) Patients. <i>Blood</i> , 2019, 134, 3148-3148.	1.4	1
149	Role of B-Cell Maturation Antigen (BCMA) Targeted Immunotherapies in Relapsed and Refractory Multiple Myeloma- a Systematic Review. <i>Blood</i> , 2019, 134, 5597-5597.	1.4	1
150	Implementation of Outpatient High-Dose Cytarabine (HiDAC) for AML: Evaluation of the Impact of Transitioned Outpatient Chemotherapy in an Oncology Care Model Setting. <i>Blood</i> , 2019, 134, 2153-2153.	1.4	4
151	Efficacy of Ibrutinib-Based Regimen in Chronic Lymphocytic Leukemia: A Systematic Review. <i>Journal of Hematology (Brossard, Quebec)</i> , 2019, 8, 1-10.	1.0	5
152	Effect of Optimal Thyroid Replacement Therapy on Chronic Hyponatremia with Focused Review of the Evidence, Mechanisms, and Clinical Implications. <i>Cureus</i> , 2019, 11, e5813.	0.5	2
153	Rapid Infusion Daratumumab Is Safe in Patients with AL Amyloidosis. <i>Blood</i> , 2019, 134, 1838-1838.	1.4	1
154	Comparative Efficacy and Safety of Once Versus Twice Weekly Carfilzomib Based Therapies in Relapsed Refractory Multiple Myeloma- a Systematic Review. <i>Blood</i> , 2019, 134, 3150-3150.	1.4	0
155	A Phase I Trial of Venetoclax in Combination with BEAM Conditioning Chemotherapy (V-BEAM) with Autologous Stem Cell Transplantation in Non-Hodgkin Lymphoma. <i>Blood</i> , 2019, 134, 5705-5705.	1.4	0
156	Antibody Based Three-Drug Regimens for Multiple Myeloma - a Systematic Review of Phase II and Phase III Clinical Trials. <i>Blood</i> , 2019, 134, 5546-5546.	1.4	0
157	Efficacy and Safety Profile of Bortezomib Based Regimens for Treatment of Newly Diagnosed Amyloidosis: A Systematic Review of Literature. <i>Blood</i> , 2019, 134, 5583-5583.	1.4	0
158	A Systematic Review on Efficacy and Safety of Lenalidomide Based Regimens for Treatment of Newly Diagnosed Amyloidosis. <i>Blood</i> , 2019, 134, 5584-5584.	1.4	0
159	Advancements in Treatment for Newly Diagnosed Frail and Elderly Myeloma Patients: A Systematic Review. <i>Blood</i> , 2019, 134, 5589-5589.	1.4	0
160	Evolving Data on CAR T-Cell Therapy for Multiple Myeloma, Novel Targets, Conditioning Regimens and Novel Constructs: A Systematic Review. <i>Blood</i> , 2019, 134, 5547-5547.	1.4	0
161	Does Obesity Influence the Efficacy of P2Y12 Inhibitors in Preventing Strokes? a Systematic Review and Meta-Analysis. <i>Blood</i> , 2019, 134, 4950-4950.	1.4	1
162	Melphalan Based Regimens for Treatment of Newly Diagnosed Amyloidosis, Lessons from Clinical Literature: A Systematic Review. <i>Blood</i> , 2019, 134, 5561-5561.	1.4	0

#	ARTICLE	IF	CITATIONS
163	Patterns of Relapse and Treatment for Relapsed/Refractory AL Amyloidosis: A Systematic Review. <i>Blood</i> , 2019, 134, 5556-5556.	1.4	0
164	Three Drug Regimens for Newly Diagnosed Multiple Myeloma Transplant-Ineligible Elderly Patients - a Systematic Review. <i>Blood</i> , 2019, 134, 5574-5574.	1.4	0
165	Depth of Pre-Treatment Immunoparesis Is an Important Prognostic Factor for Survival in Relapsed Multiple Myeloma. <i>Blood</i> , 2019, 134, 4359-4359.	1.4	0
166	Updates in Clinical Data on FDA Fast Track Drugs for Relapsed Refractory Multiple Myeloma: A Systematic Review of Literature. <i>Blood</i> , 2019, 134, 5579-5579.	1.4	0
167	Efficacy of Elotuzumab Based Combinations in Patients with Multiple Myeloma - a Systematic Review. <i>Blood</i> , 2019, 134, 5548-5548.	1.4	0
168	Efficacy and Toxicity of Lenalidomide for Treatment of Chronic Lymphocytic Leukemia: A Systematic Review and Meta-Analysis. <i>Blood</i> , 2019, 134, 5488-5488.	1.4	0
169	Update on Risk Stratification Model of Smoldering Multiple Myeloma: A Systematic Review. <i>Blood</i> , 2019, 134, 5512-5512.	1.4	0
170	Carfilzomib Based Regimens for Treatment of Newly Diagnosed Multiple Myeloma: A Systematic Review. <i>Blood</i> , 2019, 134, 5588-5588.	1.4	0
171	Yttrium-90-Ibritumomab Tiuxetan (Zevalin®) Radioimmunotherapy after Cytoreduction with ESHAP Chemotherapy in Patients with Relapsed Follicular Non-Hodgkin Lymphoma: Final Results of a Phase II Study. <i>Oncology</i> , 2018, 94, 274-280.	1.9	14
172	Efficacy and toxicity profile of carfilzomib based regimens for treatment of multiple myeloma: A systematic review. <i>Critical Reviews in Oncology/Hematology</i> , 2018, 125, 1-11.	4.4	29
173	Blocking $\alpha$ -don't eat me $\beta$ -signal of CD47-SIRP $\alpha$ in hematological malignancies, an in-depth review. <i>Blood Reviews</i> , 2018, 32, 480-489.	5.7	137
174	Cardiotoxic effects of chemotherapy: A review of both cytotoxic and molecular targeted oncology therapies and their effect on the cardiovascular system. <i>Critical Reviews in Oncology/Hematology</i> , 2018, 126, 186-200.	4.4	80
175	A Retrospective Review of Fluconazole as Antifungal Prophylaxis in the Adult and Pediatric Haploidentical Stem Cell Transplant Population. <i>Biology of Blood and Marrow Transplantation</i> , 2018, 24, S395.	2.0	1
176	Unexpected favorable outcome in a patient with high grade B-cell lymphoma with abnormalities of MYC, BCL6 and BCL2 loci. <i>Cancer Genetics</i> , 2018, 222-223, 25-31.	0.4	2
177	Emerging immune targets for the treatment of multiple myeloma. <i>Immunotherapy</i> , 2018, 10, 265-282.	2.0	19
178	Role of one, two and three doses of high-dose chemotherapy with autologous transplantation in the treatment of high-risk or relapsed testicular cancer: a systematic review. <i>Bone Marrow Transplantation</i> , 2018, 53, 1242-1254.	2.4	6
179	Prophylaxis for Hepatitis B Virus Reactivation after Allogeneic Stem Cell Transplantation in the Era of Drug Resistance and Newer Antivirals: A Systematic Review and Meta-Analysis. <i>Biology of Blood and Marrow Transplantation</i> , 2018, 24, 1483-1489.	2.0	12
180	Phase 2 Open-Label Study of Bortezomib, Cladribine, and Rituximab in Advanced, Newly Diagnosed, and Relapsed/Refractory Mantle-Cell and Indolent Lymphomas. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2018, 18, 58-64.	0.4	10

#	ARTICLE	IF	CITATIONS
181	Oncolytic reovirus sensitizes multiple myeloma cells to anti-PD-L1 therapy. <i>Leukemia</i> , 2018, 32, 230-233.	7.2	49
182	How to Prevent Hepatitis B Reactivation after Allogeneic Stem Cell Transplantation in the Era of Novel Antiviral Drugs: A Systematic Review and Meta-Analysis. <i>Biology of Blood and Marrow Transplantation</i> , 2018, 24, S371-S372.	2.0	0
183	Haematometrocolpos due to transverse vaginal septum with distal atretic vagina. <i>BMJ Case Reports</i> , 2018, 2018, bcr-2018-226741.	0.5	0
184	Aneurysmal dilation of the vein of Galen and straight sinus with resultant obstructive hydrocephalus. <i>BMJ Case Reports</i> , 2018, 2018, bcr-2018-226742.	0.5	2
185	Extrapyramidal Symptoms with Administration of Lenalidomide Maintenance Therapy for Multiple Myeloma. <i>Cureus</i> , 2018, 10, e3349.	0.5	2
186	Role of High-dose Chemotherapy and Autologous Stem Cell Transplantation for Relapsed Ewing's Sarcoma: A Case Report with Focused Review of Literature. <i>Cureus</i> , 2018, 10, e2581.	0.5	3
187	Treating Diffuse Large B Cell Lymphoma in the Very Old or Frail Patients. <i>Current Treatment Options in Oncology</i> , 2018, 19, 50.	3.0	8
188	Oncolytic Viruses for Multiple Myeloma Therapy. <i>Cancers</i> , 2018, 10, 198.	3.7	20
189	Role of High-Dose Chemotherapy and Autologous Hematopoietic Cell Transplantation for Children and Young Adults with Relapsed Ewing's Sarcoma: A Systematic Review. <i>Sarcoma</i> , 2018, 2018, 1-12.	1.3	15
190	A Systematic Review of Conventional Therapy and Role of Stem Cell Transplantation for Primary Plasma Cell Leukemia. <i>Biology of Blood and Marrow Transplantation</i> , 2018, 24, S253-S254.	2.0	1
191	Implementation of a pharmacy-managed program for the transition of chemotherapy to the outpatient setting. <i>American Journal of Health-System Pharmacy</i> , 2018, 75, e246-e258.	1.0	14
192	The Comparison of Unmanipulated Bone Marrow Versus Peripheral Blood Haploidentical Stem Cell Transplantation in Adult Acute Leukemia: A Systematic Review and Meta-Analysis. <i>Blood</i> , 2018, 132, 5768-5768.	1.4	2
193	Concomitant Use of Blinatumomab and Donor Lymphocyte Infusion for Post-Transplant Relapsed CD19 Positive Acute Lymphoblastic Leukemia: Systematic Review. <i>Blood</i> , 2018, 132, 5742-5742.	1.4	6
194	The Use of Checkpoint Inhibitors before and after Allogeneic Stem Cell Transplantation: A Double-Edged Sword. <i>Blood</i> , 2018, 132, 5722-5722.	1.4	1
195	Efficacy and Tolerability of Daratumumab in Heavily Pretreated AL Amyloidosis: A Systematic Review. <i>Blood</i> , 2018, 132, 2025-2025.	1.4	2
196	Beyond JAK2 Inhibitors: A Systematic Review of Management Strategies for Myelofibrosis. <i>Blood</i> , 2018, 132, 5484-5484.	1.4	1
197	Clinical Response and Tolerability of Selinexor in Acute Myeloid Leukemia and Other Hematologic Malignancies - a Systematic Review. <i>Blood</i> , 2018, 132, 5231-5231.	1.4	2
198	A Systematic Review and Meta-Analysis: Efficacy and Toxicity Profile of Ixazomib for Treatment of Multiple Myeloma. <i>Blood</i> , 2018, 132, 5639-5639.	1.4	2

#	ARTICLE	IF	CITATIONS
199	Histone Deacetylase Inhibitors in Myelodysplastic Syndrome. <i>Blood</i> , 2018, 132, 5528-5528.	1.4	1
200	A Single Center Retrospective Evaluation of Daratumumab Infusion Related Reactions with Split-First Dose Day 1 and Day 2 Infusion. <i>Blood</i> , 2018, 132, 5667-5667.	1.4	1
201	Economic evaluation for the US of venetoclax (VEN) versus ibrutinib (IBR) versus allogeneic hematopoietic stem-cell transplantation (HSCT) for patients (pts) with relapsed or refractory (R/R) chronic lymphocytic leukemia (CLL) with 17p deletion (del 17p).. <i>Journal of Clinical Oncology</i> , 2018, 36, 7527-7527.	1.6	2
202	Disease Milestones through Bibliometric Analysis of the Top 100 Cited Articles in Multiple Myeloma. <i>Cureus</i> , 2018, 10, e2438.	0.5	9
203	Possible Predictive Factors for In-hospital Cardiac Arrest in Patients with Cancer: A Retrospective Single Center Study. <i>Cureus</i> , 2018, 10, e2828.	0.5	2
204	Impact of Storage Lesion on Post-transfusion Rise in Hemoglobin. <i>Cureus</i> , 2018, 10, e2952.	0.5	2
205	Safety and Efficacy of Venetoclax in Relapsed Refractory Multiple Myeloma: A Systematic Review and Meta-Analysis. <i>Blood</i> , 2018, 132, 5625-5625.	1.4	0
206	Efficacy and Toxicity Profile of Elotuzumab for Multiple Myeloma: A Systematic Review and Meta-Analysis. <i>Blood</i> , 2018, 132, 5640-5640.	1.4	2
207	Elderly AML: A Five-Year Retrospective Review on Prognostic Features. <i>Blood</i> , 2018, 132, 5187-5187.	1.4	0
208	Survival Benefit of Novel Drug Combinations Using Hypomethylating Agents for Elderly Patients with Newly Diagnosed Acute Myeloid Leukemia: A Systemic Review. <i>Blood</i> , 2018, 132, 5182-5182.	1.4	0
209	Efficacy, Toxicity and Targets for Adoptive Cellular Therapy in Multiple Myeloma: A Systematic Review. <i>Blood</i> , 2018, 132, 5649-5649.	1.4	0
210	Reduced-Intensity Conditioning Versus Myeloablative Conditioning for Allogeneic Hematopoietic Cell Transplantation in Patients with Myelodysplastic Syndrome: A Systematic Review and Meta-Analysis of Randomized Trials. <i>Blood</i> , 2018, 132, 5770-5770.	1.4	0
211	Efficacy of Lenalidomide Based Three Drug Versus Two Drug Regimen for Relapsed Multiple Myeloma: A Systematic Review and Meta-Analysis of Randomized Trials. <i>Blood</i> , 2018, 132, 3239-3239.	1.4	0
212	Efficacy and Safety of Histone Deacetylase Inhibitors in Multiple Myeloma - a Systematic Review of Early Phase Clinical Trials. <i>Blood</i> , 2018, 132, 5629-5629.	1.4	1
213	Efficacy and Safety of Daratumumab Based Regimens for Multiple Myeloma: A Systematic Review and Meta-Analysis. <i>Blood</i> , 2018, 132, 3292-3292.	1.4	0
214	Presentation Pattern, Diagnostic Markers, Management and Outcome of IgD Multiple Myeloma: A Systematic Review. <i>Blood</i> , 2018, 132, 3309-3309.	1.4	0
215	Presentation Patterns and Management Strategies for Central Nervous System Involvement in Multiple Myeloma: A Systematic Review of Literature. <i>Blood</i> , 2018, 132, 1951-1951.	1.4	3
216	Efficacy and Toxicity Profile of Ibrutinib Based Regimens for Refractory Multiple Myeloma: A Systematic Review. <i>Blood</i> , 2018, 132, 1948-1948.	1.4	0

#	ARTICLE	IF	CITATIONS
217	Venous Thromboembolism with Contemporary Lenalidomide-Based Regimens and Adequate Thromboprophylaxis in Newly Diagnosed Multiple Myeloma: A Systemic Review and Meta-Analysis. Blood, 2018, 132, 4835-4835.	1.4	0
218	Targeting Intracellular Signaling Cascades for Patients with Relapsed, Refractory Multiple Myeloma: A Systematic Review of Clinical Trials. Blood, 2018, 132, 5659-5659.	1.4	0
219	Diagnostic and Prognostic Role of Fecal Calprotectin As a Biomarker for Gastrointestinal Graft Versus Host Disease: A Systematic Review of Literature. Blood, 2018, 132, 5725-5725.	1.4	0
220	A Network Meta-Analysis of Clinical Trials Assessing Induction Chemotherapy in Newly Diagnosed Acute Myeloid Leukemia Among Young Adults. Blood, 2018, 132, 1432-1432.	1.4	0
221	Clinical Efficacy of Intracellular Molecular Inhibitors for Relapsed, Refractory Multiple Myeloma: A Systematic Review of Early Clinical Data. Blood, 2018, 132, 1950-1950.	1.4	0
222	The Healthcare Burden of Emergency Department Utilization for Multiple Myeloma: A Five Years U.S. Nationwide Study. Blood, 2018, 132, 3562-3562.	1.4	0
223	Antibodies in Development for Multiple Myeloma: A Systematic Review. Blood, 2018, 132, 5656-5656.	1.4	0
224	A Decade of Anti-Myeloma Vaccine Development through Early Phase Trials: A Systematic Review. Blood, 2018, 132, 5635-5635.	1.4	0
225	Evidence Based Recommendations for Supportive Care in Multiple Myeloma. Blood, 2018, 132, 1952-1952.	1.4	0
226	Gene Therapy for Thalassemia and Sickle Cell Anemia Poses Acceptable Toxicity and Efficacy: Clinical Outcomes in Forty-Seven Cases. Blood, 2018, 132, 2194-2194.	1.4	0
227	Role of Ibrutinib Based Regimen in Chronic Lymphocytic Leukemia. Blood, 2018, 132, 5563-5563.	1.4	0
228	Promising Clinical Efficacy and Toxicity Profile of Isatuximab Based Regimens for Treatment of Newly Diagnosed and Relapsed/Refractory Multiple Myeloma: A Systematic Review. Blood, 2018, 132, 1949-1949.	1.4	0
229	Efficacy and Safety Profile of Novel Alkylators in Combination Regimens for Patients with Multiple Myeloma: A Review of Literature. Blood, 2018, 132, 5626-5626.	1.4	0
230	Impact of Newer Agents on Progression Free Survival of Multiple Myeloma in the 2nd 3rd and 4th Line Setting- a Systematic Review. Blood, 2018, 132, 5645-5645.	1.4	0
231	National Trends in Leukemia Related Emergency Department Visits, Health Care Burden and Disposition Rate in the United States, 2010-2014. Blood, 2018, 132, 4695-4695.	1.4	0
232	Efficacy of Bortezomib Based Regimens and Disease Monitoring in Light Chain Multiple Myeloma: A Review of Literature. Blood, 2018, 132, 5624-5624.	1.4	0
233	Myelofibrosis Drug Development through the Decade: Novel JAK Inhibitors. Blood, 2018, 132, 5477-5477.	1.4	0
234	Efficacy of Newer Combinations and Fibril-Targeting for AL Amyloidosis: A Systematic Review of Transplant and Innovative Non-Transplant Therapies. Blood, 2018, 132, 5763-5763.	1.4	0



#	ARTICLE	IF	CITATIONS
235	Outcomes of T-Cell Depleted Haploidentical Peripheral Blood Stem Cell Transplantation for Adult Acute Leukemia: A Meta-Analysis. <i>Blood</i> , 2018, 132, 5779-5779.	1.4	0
236	Efficacy and Safety of Newer Targeted Immunotherapy for Multiple Myeloma. <i>Blood</i> , 2018, 132, 5650-5650.	1.4	0
237	Sequencing Therapy for Elderly Chronic Lymphocytic Leukemia Patients in the Era of Novel Therapies: An Overview of Randomized Clinical Trials. <i>Blood</i> , 2018, 132, 5559-5559.	1.4	0
238	Pomalidomide Based Regimens for Treatment of Relapsed Multiple Myeloma: A Systematic Review and Meta-Analysis of Clinical Trials. <i>Blood</i> , 2018, 132, 2022-2022.	1.4	0
239	Rare Isolated Renal Involvement with Marginal Zone B Cell Lymphoma: A Case Report with Literature Review of Contemporary Management Strategies. <i>Cureus</i> , 2018, 10, e3560.	0.5	0
240	Expanded safety analysis of pevonedistat, a first-in-class NEDD8-activating enzyme inhibitor, in patients with acute myeloid leukemia and myelodysplastic syndromes. <i>Blood Cancer Journal</i> , 2017, 7, e520-e520.	6.2	29
241	Donor origin CAR T cells: graft versus malignancy effect without GVHD, a systematic review. <i>Immunotherapy</i> , 2017, 9, 123-130.	2.0	78
242	Potential application and prevalence of the CD30 (Ki-1) antigen among solid tumors: A focus review of the literature. <i>Critical Reviews in Oncology/Hematology</i> , 2017, 113, 8-17.	4.4	12
243	Mixed phenotype acute leukemia with t(9;22): success with nonacute myeloid leukemia-type intensive induction therapy and stem cell transplantation. <i>Clinical Case Reports (discontinued)</i> , 2017, 5, 435-439.	0.5	2
244	A Review of Autologous Stem Cell Transplantation in Lymphoma. <i>Current Hematologic Malignancy Reports</i> , 2017, 12, 217-226.	2.3	73
245	Delayed rhabdomyolysis with paclitaxel, ifosfamide, carboplatin, and etoposide regimen: a case report. <i>Journal of Medical Case Reports</i> , 2017, 11, 100.	0.8	9
246	Post-Allogeneic Stem Cell Transplantation Maintenance Dasatinib in Philadelphia Chromosome Positive Acute Leukemia. <i>Biology of Blood and Marrow Transplantation</i> , 2017, 23, S289.	2.0	5
247	Fluconazole 200mg Daily As Antifungal Prophylaxis in Allogeneic Hematopoietic Stem Cell Transplant Recipients: A Retrospective Review. <i>Biology of Blood and Marrow Transplantation</i> , 2017, 23, S192.	2.0	1
248	High Dose Chemotherapy with Autologous Stem Cell Transplant in Treatment of Germ Cell Tumors: A Systematic Review and Meta-Analysis. <i>Biology of Blood and Marrow Transplantation</i> , 2017, 23, S269-S270.	2.0	0
249	Waldenström Macroglobulinemia: Review of Pathogenesis and Management. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2017, 17, 252-262.	0.4	38
250	Brentuximab vedotin for treatment of non-Hodgkin lymphomas: A systematic review. <i>Critical Reviews in Oncology/Hematology</i> , 2017, 109, 42-50.	4.4	59
251	Anti-CD 19 and anti-CD 20 CAR-modified T cells for B-cell malignancies: a systematic review and meta-analysis. <i>Immunotherapy</i> , 2017, 9, 979-993.	2.0	21
252	Bone lymphoma with multiple negative bone biopsies. <i>JAAPA: Official Journal of the American Academy of Physician Assistants</i> , 2017, 30, 27-29.	0.3	0



#	ARTICLE	IF	CITATIONS
253	Coccidioidomycosis, immunoglobulin deficiency: safety challenges with CAR T cells therapy for relapsed lymphoma. <i>Immunotherapy</i> , 2017, 9, 1061-1066.	2.0	9
254	Rare transformation to double hit lymphoma in Waldenstrom's macroglobulinemia. <i>Immunotherapy</i> , 2017, 9, 709-714.	2.0	1
255	Intractable cerebral <i>Nocardia mexicana</i> in a GvHD patient successfully treated with linezolid. <i>Bone Marrow Transplantation</i> , 2017, 52, 1476-1478.	2.4	8
256	Quetiapine Associated Thrombotic Thrombocytopenic Purpura: A Case Report and Literature Review. <i>American Journal of Therapeutics</i> , 2017, 24, e615-e616.	0.9	3
257	Cardiovascular Oncologic Emergencies. <i>Cardiology</i> , 2017, 138, 147-158.	1.4	15
258	<i>Clostridium difficile</i> Infection in Hematopoietic Stem Cell Transplant Patients: A Single-center Experience. <i>Open Forum Infectious Diseases</i> , 2017, 4, S390-S390.	0.9	0
259	Limitations of routine skeletal survey: detection of critical but asymptomatic cervical spine lesion in multiple myeloma. <i>BMJ Case Reports</i> , 2017, 2017, bcr-2017-221231.	0.5	0
260	Allogeneic Transplant in ELANE and MEFV Mutation Positive Severe Cyclic Neutropenia: Review of Prognostic Factors for Secondary Severe Events. <i>Case Reports in Hematology</i> , 2017, 2017, 1-7.	0.4	4
261	Cost effectiveness of carfilzomib (CAR), ixazomib (IXA), elotuzumab (ELO), or daratumumab (DAR) with lenalidomide and dexamethasone (LEN+DEX) vs LEN+DEX in relapsed/refractory multiple myeloma (R/R). <i>TJ ETQq1 116784314 rgBT /C</i>		
262	Rapunzel syndrome: a rare cause of hypoproteinaemia and review of literature. <i>BMJ Case Reports</i> , 2016, 2016, bcr2016216600.	0.5	14
263	Posterior reversible encephalopathy syndrome in malignant hypertension secondary to focal segmental glomerulosclerosis. <i>BMJ Case Reports</i> , 2016, 2016, bcr2016216512.	0.5	3
264	Successful recovery and allogeneic stem cell transplant following chemotherapy-induced severe cardiomyopathy: literature review of management and prognostic factors. <i>BMJ Case Reports</i> , 2016, 2016, bcr2016217210.	0.5	2
265	Case of relentless chronic phase of chronic myeloid leukaemia. <i>BMJ Case Reports</i> , 2016, 2016, bcr2016215370.	0.5	1
266	Blinatumomab-induced donor T-cell activation for post-stem cell transplant-relapsed acute CD19-positive biphenotypic leukemia. <i>Immunotherapy</i> , 2016, 8, 847-852.	2.0	7
267	Outcome Comparison of Allogeneic versus Autologous Stem Cell Transplantation in Transformed Low-Grade Lymphoid Malignancies: A Systematic Review and Pooled Analysis of Comparative Studies. <i>Acta Haematologica</i> , 2016, 136, 244-255.	1.4	10
268	Cost and Outcome Analysis of Autologous Peripheral Blood Stem Cell Mobilization with Plerixafor and G-CSF vs. Cyclophosphamide and G-CSF in Patients with Multiple Myeloma: A Reassessment in View of Increased Costs of Cyclophosphamide. <i>Biology of Blood and Marrow Transplantation</i> , 2016, 22, S270.	2.0	0
269	Retrospective review of intravenous pentamidine for <i>Pneumocystis</i> pneumonia prophylaxis in allogeneic hematopoietic stem cell transplantation. <i>Transplant Infectious Disease</i> , 2016, 18, 63-69.	1.7	13
270	Treatment of refractory <i>ITP</i> and Evans syndrome by haematopoietic cell transplantation: is it indicated, and for whom?. <i>Vox Sanguinis</i> , 2016, 110, 5-11.	1.5	9

#	ARTICLE	IF	CITATIONS
271	Factors associated with improved outcomes after second allogeneic hematopoietic cell transplantation for relapsed pediatric leukemia. <i>Annals of Hematology</i> , 2016, 95, 637-644.	1.8	13
272	Role of Maintenance Therapy after High-Dose Chemotherapy and Autologous Hematopoietic Cell Transplantation in Aggressive Lymphomas: A Systematic Review. <i>Biology of Blood and Marrow Transplantation</i> , 2016, 22, 1182-1196.	2.0	6
273	First reported association of chronic lymphocytic leukaemia and interstitial granulomatous dermatitis. <i>BMJ Case Reports</i> , 2016, 2016, bcr2016215108.	0.5	3
274	Anti-CD 19 and Anti- CD 20 Chimeric Antigen Receptor-Modified T Cells for B-Cell Malignancies: A Systematic Review and Meta-Analysis. <i>Blood</i> , 2016, 128, 5163-5163.	1.4	1
275	Safety and Efficacy of Plerixafor on a Convenient Dose Schedule to Facilitate Outpatient Hematopoietic Stem Cell Collection for Autologous Hematopoietic Transplantation. <i>Blood</i> , 2016, 128, 5736-5736.	1.4	1
276	Outcome of Immune-Suppressive Therapy (IST) and Hematopoietic Stem Cell Transplantation (SCT) in Patients with Aplastic Anemia: A Retrospective Single Center Experience. <i>Blood</i> , 2016, 128, 5081-5081.	1.4	0
277	High Dose Chemotherapy with Autologous Stem Cell Transplant in Treatment of Germ Cell Tumors: A Systematic Review and Meta-Analysis. <i>Blood</i> , 2016, 128, 5829-5829.	1.4	0
278	Retrospective Review of Intravenous Pentamidine for Pneumocystis Pneumonia Prophylaxis in Patients Undergoing Hematopoietic Stem Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2015, 21, S367.	2.0	0
279	Severe Refractory Immune Thrombocytopenia Successfully Treated with High-Dose Pulse Cyclophosphamide and Eltrombopag. <i>Case Reports in Hematology</i> , 2015, 2015, 1-3.	0.4	7
280	Plerixafor as a salvage mobilization strategy for haploidentical peripheral blood allogeneic stem cell transplantation. <i>Clinical Case Reports (discontinued)</i> , 2015, 3, 728-730.	0.5	6
281	Spontaneous tumour lysis syndrome associated with contrast dye iohexol use in mantle cell lymphoma. <i>BMJ Case Reports</i> , 2014, 2014, bcr2014204113-bcr2014204113.	0.5	6
282	Dasatinib-induced pulmonary hypertension in chronic myelogenous leukaemia. <i>BMJ Case Reports</i> , 2014, 2014, bcr2014204477-bcr2014204477.	0.5	12
283	NK/T-cell non-Hodgkin's lymphoma with secondary haemophagocytic lymphohistiocytosis treated with matched unrelated donor allogeneic stem cell transplant. <i>BMJ Case Reports</i> , 2014, 2014, bcr2014205602-bcr2014205602.	0.5	4
284	Lymphomatous orbital infiltration and vision loss in diffuse large B-cell lymphoma. <i>BMJ Case Reports</i> , 2014, 2014, bcr2014204613-bcr2014204613.	0.5	1
285	Nephrotic Syndrome Secondary to Proliferative Glomerulonephritis with Monoclonal Immunoglobulin Deposits of Lambda Light Chain. <i>Case Reports in Nephrology</i> , 2014, 2014, 1-6.	0.4	2
286	Acute renal failure and type B lactic acidosis as first manifestation of extranodal T-cell lymphoblastic lymphoma. <i>BMJ Case Reports</i> , 2014, 2014, bcr2014205044-bcr2014205044.	0.5	4
287	MLN4924, a Novel Investigational Inhibitor Of NEDD8-Activating Enzyme (NAE), In Adult Patients With Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS): Results From Multiple Dosing Schedules In a Phase 1 Study. <i>Blood</i> , 2013, 122, 1443-1443.	1.4	4
288	Initial Mobilization of Autologous Peripheral Blood Stem Cells With Granulocyte Colony-Stimulating Factor and Plerixafor in Patients With Multiple Myeloma: A Prospective Comparison in Lenalidomide- and Non-Lenalidomide-Treated Patients. <i>Biology of Blood and Marrow Transplantation</i> , 2011, 17, S201.	2.0	1

#	ARTICLE	IF	CITATIONS
289	Effective Primary Mobilization of Autologous Peripheral Blood Stem Cells with Granulocyte Colony-Stimulating Factor and Plerixafor in Lenalidomide-Treated Patients with Multiple Myeloma. Blood, 2010, 116, 2254-2254.	1.4	2
290	Pentostatin and Alemtuzumab: An Immunosuppressive Nonmyeloablative Preparative Regimen for Allogeneic Peripheral Blood Stem Cell Transplantation (PBSCT).. Blood, 2009, 114, 4312-4312.	1.4	0
291	Efficacy and safety of regimens used for the treatment of multicentric Castleman disease: A systematic review. European Journal of Haematology, 0, , .	2.2	3